Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04316975 · ClinicalTrials.gov registry record · NA

Utility Of Mutational Load As A Predictor For Endoscopic Treatment Response In Barrett's Esophagus

A NA study, sponsored by University of North Carolina, Chapel Hill.

Completed
Registry status
NA
Development phase
75
Enrollment target

NCT04316975 is a NA study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 75 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04316975, a NA study, has completed, sponsored by University of North Carolina, Chapel Hill.

COMPLETED
Registry status
NA
Development phase
75 participants
Enrollment target

Study Summary

To evaluate association between mutational load (ML) from esophageal biopsy specimens in pre-endoscopic eradication therapy (EET) in Barrett's Esophagus (BE) or Intramucosal adenocarcinoma (IMC) patients and treatment resistance (treatment resistance will be defined as disease recurrence and/or need for additional intervention such as increased acid suppression, need for anti-reflux surgery, or use of alternate ablative modality).

Interventions

  • OTHER Study Driven Procurement of Biopsies

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2020-04-10
Est. Completion 2023-12-20
Phase NA

What the Registry Record Tells You About NCT04316975

The ClinicalTrials.gov registry entry for NCT04316975 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Study Driven Procurement of Biopsies is the first listed.

NCT04316975 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04316975 about?

NCT04316975 is a clinical study titled "Utility Of Mutational Load As A Predictor For Endoscopic Treatment Response In Barrett's Esophagus". To evaluate association between mutational load (ML) from esophageal biopsy specimens in pre-endoscopic eradication therapy (EET) in Barrett's Esophagus (BE) or Intramucosal adenocarcinoma (IMC) patients and treatment resistance (treatment resistance will be defined as disease recurrence and/or need...

What is the current status of trial NCT04316975?

This trial is currently completed. It is a NA study. The enrollment target is 75 participants. The study started on 2020-04-10. Estimated completion is 2023-12-20.

What interventions are being tested in trial NCT04316975?

The interventions under investigation include: Study Driven Procurement of Biopsies (OTHER).

Who is sponsoring clinical trial NCT04316975?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.